Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2024-01-07 Transaction in Own Shar…
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Notification of cessation of securities - TLX 4 pages 24.6KB
Transaction in Own Shares Classification · 95% confidence The document is titled 'Notification of cessation of +securities' and details the lapse of conditional rights to securities (share rights and share appreciation rights) for Telix Pharmaceuticals Limited. It provides specific information about the securities that have ceased, reasons for cessation, and updated issued capital figures. There is no indication of financial statements, management discussion, or regulatory certifications. The document is an announcement about changes in the company's issued capital related to securities lapsing, which fits the category of Transaction in Own Shares (POS) as it relates to the company's own equity instruments ceasing to exist or lapsing. The document length is about 4947 characters, and it is a detailed announcement rather than a brief note or a report publication announcement. Therefore, the best classification is POS.
2024-01-07 English
Notification regarding unquoted securities - TLX 7 pages 32.0KB
Share Issue/Capital Change Classification · 95% confidence The document is a detailed notification regarding the issue of unquoted equity securities by Telix Pharmaceuticals Limited. It includes specifics about the types and numbers of securities issued, dates of issuance, and references to employee incentive schemes. The document is structured as an official announcement to the ASX (Australian Securities Exchange) about securities issued under employee incentive plans, including share rights and share appreciation rights. It does not contain financial statements, audit information, or management discussion of financial results. It is not a report or presentation but a formal notification of securities issuance. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues or capital changes. The document length (7316 characters) and content confirm it is a full notification rather than a brief announcement or a report publication notice. Therefore, the correct classification is SHA with high confidence.
2024-01-07 English
JP Morgan Healthcare Conference and Trading Update 2 pages 191.3KB
Investor Presentation Classification · 95% confidence The document is an ASX release titled 'Presentation to J.P. Morgan Healthcare Conference and Q4 Revenue Update' dated 8 January 2024. It includes a presentation announcement for the J.P. Morgan Healthcare Conference and provides unaudited revenue updates for Q4 2023 and FY 2023. The document mentions the upcoming full year financial results report for the year ended 31 December 2023 to be released on 22 February 2024. The content focuses on investor presentation details, revenue highlights, and conference participation rather than a full financial report or detailed financial statements. The document is longer than 5,000 characters and contains substantive financial data (revenue figures), but it is primarily a presentation and update rather than a comprehensive financial report. Therefore, it fits best as an Investor Presentation (IP).
2024-01-07 English
JP Morgan Healthcare Conference Presentation 31 pages 2.4MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation from Telix Pharmaceuticals Limited, focusing on their product pipeline, clinical trials, financial updates, and strategic growth plans. It includes forward-looking statements, unaudited financial figures for FY2023, descriptions of clinical trial phases, and commercial stage products. The content is structured as a comprehensive investor presentation with charts, product descriptions, and development milestones. There is no indication that this is an official annual report, earnings release, or regulatory filing. The presence of forward-looking statements, detailed pipeline information, and financial updates aligns with the characteristics of an Investor Presentation (IP). The document length (15,000 characters) and detailed content further support this classification rather than a brief announcement or report publication notice.
2024-01-07 English
Telix Plans U.S. Registered Public Offering and Listing 2 pages 127.9KB
Capital/Financing Update Classification · 95% confidence The document is an ASX release announcing Telix Pharmaceuticals Limited's planned registered public offering and listing in the United States. It discusses the intention to file a registration statement with the SEC and the potential IPO of American Depositary Shares. The text is an announcement of a financing event and capital market activity, not a full financial report or detailed financial data. It does not contain actual financial statements or comprehensive financial analysis. The document length is 5169 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2024-01-04 English
Application for quotation of securities - TLX 7 pages 31.2KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into ordinary fully paid shares. It includes specifics about the number of securities, issue dates, and prices. This type of document is related to changes in the company's capital structure, specifically the issuance and quotation of new shares resulting from option exercises. It is not a financial report, earnings release, or management discussion, but rather an announcement about capital changes. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and content confirm it is a full announcement, not just a brief notice or regulatory filing.
2023-12-21 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.